Quince Therapeutics files resale prospectus for up to 6.67M shares plus warrants; company gets no proceeds

Filed August 5, 2025 · ~1 min read

Key Changes

• high

  This is a secondary offering: selling stockholders are offering up to 6,671,928 shares, and Quince will not receive any proceeds from those sales.

  The Offering verify on EDGAR →
• high

  The prospectus also covers up to 2,000,000 shares underlying pre-funded warrants and up to 8,671,928 shares underlying common stock warrants.

  The Offering verify on EDGAR →
• high

  Quince may receive cash only if the pre-funded warrants or common stock warrants are exercised for cash.

  The Offering verify on EDGAR →